Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells by unknown
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Application of tumor cell surface adhesion molecule EpCAM-dependent antibody capture, and intracellular cytokerat-
ins (CKs)-dependent immunostaining strategies to detect disseminated or circulating tumor cells (DTCs or CTCs), 
is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs and DTCs, 
particularly in their capturing and identifying CTCs/DTCs shed from diverse types of solid tumor, thus being biased 
and restricted to the only both EpCAM and CK positive cancer cells. Moreover, heterogeneity of chromosome and 
tumor biomarker of CTCs/DTCs cannot be co-examined by conventional CK/EpCAM-dependent techniques. Accord-
ingly, a novel integrated cellular and molecular approach of EpCAM-independent subtraction enrichment (SE) and 
immunostaining-FISH (iFISH®) has recently been successfully developed. SE-iFISH® is able to effectively enrich, 
comprehensively identify and characterize both large and small size non-hematopoietic heteroploid CTCs, DTCs and 
circulating tumor microemboli in various biofluid specimens of either cancer patients or patient-derived-xenograft 
mice. Obtained tumor cells, free of anti-EpCAM perturbing and hypotonic damage, are eligible for primary tumor 
cell culture as well as a series of downstream analyses. Highly heterogeneous CTCs and DTCs could be classified into 
subtypes by in situ phenotyping protein expression of various tumor biomarkers and karyotyping of chromosome 
aneuploidy performed by iFISH®. Each CTC subtype may correlate with distinct clinical significance in terms of tumor 
metastasis, relapse, therapeutic drug sensitivity or resistance, respectively.
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Background
Circulating tumor cells (CTCs) are cancer cells shed from 
primary or metastatic solid tumors into peripheral blood 
[1], whereas disseminated tumor cells (DTCs) are neo-
plastic cells disseminated into biofluid, including bone 
marrow, ascites, pleural effusion, cerebrospinal fluid 
(CSF), and urine, etc. [2]. CTCs play a fundamental role 
in tumor distant metastasis. Clinical utilities of detec-
tion of CTCs are summarized in Fig.  1. In particular, 
quantitative and qualitative examination of CTCs have 
been applied to rapidly evaluate efficacy of chemo- and 
targeted therapy, predict prognosis, monitor therapeutic 
drug resistance and cancer relapse in real time. Detection 
of CTCs and DTCs is the most representative of “liquid 
biopsy” due to its unique availability of frequent and non-
invasive detecting and monitoring tumor cells in biofluid 
and peripheral blood of cancer patients. The American 
Society of Clinical Oncology has accepted quantification 
of CTCs as a novel breast cancer biomarker [3].
Various methodologies regarding detection of CTCs 
and DTCs were substantially discussed [4]. An effective 
detection of CTCs/DTCs is constituted by approaches 
including both efficient isolation and adequate identifi-
cation. However, efforts reported to date with respect to 
enhancing CTCs/DTCs detection have mainly focused 
on improving either isolation or identification, rarely on 
both.
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Isolation of CTCs and DTCs
Most of the recognized methodologies for isolating CTCs 
and DTCs could be classified as cell filtration, antibody 
capture and enrichment.
Cell filtration
The principle of cell filtration (such as ISET) [5] for iso-
lating CTCs relies on the assumption that CTCs are 
larger than white blood cells (WBCs). Such technique is 
able to rapidly isolate clusters of CTCs [circulating tumor 
microemboli (CTM)] and the single CTC only with the 
size larger than WBCs. However, recent studies demon-
strated the existence of plenty of CTCs and DTCs with 
the size either similar or smaller than that of WBCs in 
both patients [6–8] or patient derived xenograft (PDX) 
tumor animal models [7, 9], suggesting that cell size-
based filtration may lose significant amount of small 
CTCs and DTCs [10–12]. Considering CTCs undergo-
ing epithelial-mesenchymal transition (EMT) are smaller 
in size [13], and many small CTCs are clinically relevant 
[9, 14], inherent limitation of cell filtration technique on 
detection of highly heterogeneous populations of CTC 
and DTC should not be ignored.
Antibody capture
Anti-epithelial cell adhesion molecule (EpCAM)-derived 
technologies, including CellSearch [1] and microfludics 
or CTC-chip [4, 15], constitute the current antibody cap-
ture strategy.
Nevertheless, emerging evidence has revealed highly 
dynamic localization and expression of EpCAM on 
tumor cells. EpCAM was found on the plasma mem-
brane, in lysosome or nucleus [16, 17]. Intracellular 
domain of EpCAM could localize in nucleus and plays a 
fundamental role in signaling pathways [18]. High expres-
sion of EpCAM was reported on epithelial neoplastic 
cells in primary and metastatic lesions, however, low on 
CTCs derived from solid tumors [16]. Heterogeneous 
expression of EpCAM on cancer cells among different 
tissue or even within the same sample was observed [16, 
19]. Recent quantitative study performed by flow-cytom-
etry demonstrated that bladder T24 and melanoma SK-
Mel-28 cancer cells showed low and non-expression 
of EpCAM, respectively, compared to that on SK-BR-3 
breast cancer cells [7]. Additional extended immu-
nostaining comparison of EpCAM expression illustrated 
in Fig.  2 showed that only colon cancer cells SW480 
had strong EpCAM staining on the plasma membrane, 
whereas both pancreatic cancer cells PANC-1and non-
small cell lung cancer (NSCLC) cells A549 only showed 
very weak and heterogeneous cytoplasmic and nucleus 
staining. Though characteristics of cell line cells are not 
identical to parental tumor cells, revealed insufficient or 
absence of EpCAM on the plasma membrane may par-
tially account for the ineffective detection of CTCs by 
anti-EpCAM-dependent strategies in most NSCLC and 
pancreatic cancer as well as many other types of cancer 
patients. Interestingly, observed heterogeneous nuclear 
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Fig. 1 Summary of clinical significance of detecting CTCs. Clini-
cal utilities of detection of CTCs, which are classified into four main 
categories of prior (blue), under (red) and post (green) therapy as well 
as R&D (yellow), are summarized in the subway map. Distinct signifi-
cance of CTC is shown at different station




Fig. 2 Comparison of EpCAM expression among different types of 
cancer cell. IF staining of EpCAM was performed on adenocarcinoma 
cells of colon (SW480), pancreas (PANC-1) and NSCLC (A549). SW480 
cells show very high expression of EpCAM on the plasma membrane. 
Most of PANC-1cells have very low amount of EpCAM localized in 
cytoplasm and vesicles, and one out of five cells shows EpCAM in 
nucleus (green arrow). All of A549 cells, except two negative in the 
middle (white arrows), have weak nucleus staining of EpCAM. Plasma 
membrane localization of EpCAM is not visualized on both PANC-1 
and A549 cells
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line cells in this study seems keeping in accordance with 
the similar previously published observation on thyroid 
tumor cells [17].
Besides cancer cell line cells, absence of EpCAM on as 
high as 30 % of the examined 134 epithelial solid tumors 
was also reported [20]. Additionally, it has been recently 
recognized that only EpCAM-negative CTCs in breast 
cancer patients possess enhanced metastasizing potential 
to brain [21], though phenotypic existence of EpCAM on 
metastasis-initiating cells (MICs) among CTC has been 
demonstrated [22]. Inherit absence or down-regulation 
of EpCAM which associates with EMT and cancer pro-
gression as well as metastasis [21, 23], inevitably result in 
failure to isolate those “uncapturable” CTCs by means of 
anti-EpCAM or its derived techniques [19, 24].
Intracellular signaling pathways are triggered follow-
ing antibody binding and crosslinking of cell surface 
molecules [25]. It is reasonable to speculate that bio-
characterization of CTCs isolated by anti-EpCAM might 
be perturbed with unpredictable artifacts upon anti-
body binding to EpCAM, an active signaling molecule 
on tumor cells [16, 18, 26, 27]. Indeed, anti-EpCAM has 
been recently reported to induce proliferation and modu-
late gene expression in human lung cancer cells A549 
[28].
Enrichment
Negative enrichment is the most recognized enrichment 
technique for isolating CTCs. The procedure applies 
both hypotonic lysis to remove red blood cells (RBCs) 
and anti-CD45 antibody to deplete WBCs at a depletion 
efficiency range of 2–3 logs [12, 29]. However, significant 
amounts of post-negative enrichment residual WBCs, 
deleterious hypotonic damage and loss of CTCs follow-
ing hemolysis [11, 12, 29], severely interfere subsequent 
accurate detection, analysis and primary tumor cell cul-
ture of CTCs.
Accordingly, a novel enrichment strategy–Subtraction 
Enrichment (SE), which is distinguished from the con-
ventional negative enrichment, has been developed [7]. 
Particularly, strategies of non-hemolytic removal of RBCs 
and application of immunomagnetic beads conjugated 
to a cocktail of anti-multiple WBC markers antibodies, 
ensure both minimum hypotonic injury to CTCs/DTCs 
and maximal removal of WBCs (as high as 4–5 logs). 
In addition, special coating of the immuno-beads keeps 
non-specific binding of non-hematopoietic tumor cells to 
the magnetic particles at minimum. Since SE strategy was 
reported for the first time to successfully isolate lung can-
cer CTCs in 2009 [30], substantial improvement has been 
made to render its maximum efficiency and optimized 
flexibility for enrichment of CTCs, DTCs and CTM in 
various specimens of different types of cancer patients 
[31] or tumor mouse models [9], despite how EpCAM is 
heterogeneously expressed or cell size is varied.
Rapidly enriched CTCs/DTCs which are unperturbed 
by antibody and free of hypotonic damage are eligible for 
primary tumor cell culture (our unpublished results) and 
several downstream analyses performed on either pooled 
or single tumor cell.
Identification of CTCs and DTCs
Currently, nucleic acid analysis and immunostaining 
of epithelial marker protein [such as cytokeratin (CK)] 
are the most frequently published techniques for CTC 
identification.
Nucleic acid‑based analyses
Nucleic acid-based analyses of tumor biomarkers for 
detecting CTCs were well summarized [4]. PCR, RT-
PCR or next generation sequencing (NGS) have been 
applied to detect CTC-derived DNA or mRNA in 
plasma. Recently developed RNA in  situ hybridiza-
tion (RNAish) technique (Affymetrix, Santa Clara, CA, 
USA) demonstrated its capability for visible identifying 
mRNA in CTCs. However, availability of the true tumor 
specific target genes and appropriate interpretation of 
both positive and negative results still remains a signifi-
cant challenge and a concern. Moreover, expression and 
post-translational modification of tumor biomarker pro-
teins, which ultimately play a key biological role in neo-
plastic cells, cannot be revealed by nucleic acid-based 
technologies.
Immunostaining
Confirmatory immunocytochemistry [7] or immunofluo-
rescent (IF) staining of the intracellular epithelial marker 
CK currently constitutes the primary CTC identification 
approach [1]. However, it has been recognized that dur-
ing EMT, down-regulation of CK is part of an oncogenic 
pathway that increases tumor invasiveness and metastatic 
potential [19, 24, 32]. Loss of CKs in tumor cells closely 
associates with a higher grade and mitotic index in breast 
cancer patients [32]. Existence of CK negative “invisible” 
tumor cells significantly interferes precise detection of 
CTCs and DTCs performed by immunostaining of CKs 
alone [19, 33, 34]. It is therefore imperative to develop 
an alternative strategy, regardless of the type and stage 
of cancer as well as CK expression, to effectively identify 
heterogeneous CTCs and DTCs.
Immunostaining‑FISH (iFISH®)
Aneuploidy of chromosome(s) in neoplastic cells of dif-
ferent types of cancer has been reported elsewhere. Het-
eroploid chromosome 8 identified by centromere probe 
(CEP 8)-FISH was observed in cancer cells from tissue of 
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lung [35], esophageal [36], pancreatic [37], gastric [38], 
colon [39], bladder [40] and hepatocellular [41] carcino-
mas, etc. However, the similar FISH approach applied 
to identify CTCs/DTCs is complicated due to inher-
ent bio-complicacy of hematopoietic WBCs and non-
hematopoietic tumor cells [42, 43]. Moreover, similar to 
nucleic acid-based detection, expression of a series of 
tumor biomarker proteins on/in CTCs and DTCs cannot 
be revealed and examined by conventional FISH method.
Currently, EpCAM and CK are taken as epithelial 
markers for capturing and identifying CTCs/DTCs, 
respectively [1, 4]. However, heterogeneous expression 
or absence of EpCAM and CKs on tumor cells restricts 
relevant technologies to detect those neoplastic cells. 
Besides being the “epithelial marker”, dual properties of 
tumor “biomarker” of both EpCAM [16, 18, 26, 27] and 
CKs [44] have been demonstrated.
Diverse clinical outcomes were found to correlate with 
quantity of EpCAM expressed on the tumor cells among 
different types of cancer. In the case of prostate cancer, 
overexpressed EpCAM associated with progression and 
distant metastasis [45], whereas increased 10-year sur-
vival rate of gastric cancer patients was confirmed to 
correlate with the increased EpCAM [46]. In contrast, 
decreased EpCAM was demonstrated to closely correlate 
with progression, budding and metastasis of both breast 
and colon cancers [21, 47].
Post-translational modification of intracellular CK18 
protein revealed by phenotypic immunostaining, has 
been reported to correlate with differentiation of hepa-
tocellular carcinoma (HCC) [48]. Down-regulated CK18 
protein seemed to promote cell migration [49] and pro-
gression of breast [34], nasopharyngeal [44] as well as 
colon cancers [50], though up-regulated CK18 pro-
tein was shown to correlate with poor differentiation, 
advanced stage, metastasis and recurrence in lung [51], 
renal cell [52], oral cavity [53], and esophageal squamous 
cell carcinomas [54]. Similar to the caspase cleaved extra-
cellular CK18 fragment which is a serum biomarker of 
tumor cell apoptosis [55], its intracellular counterpart, 
the intact CK18 apparently is an important tumor bio-
marker with clinical significance. However, characteri-
zation of tumor biomarker CK18 and its distinct clinical 
relevance in CTCs/DTCs have not been specifically 
addressed previously.
In view of the extraordinary significance in terms 
of simultaneous phenotyping tumor biomarker pro-
tein expression and karyotyping aneuploidy of 
chromosome(s) in CTCs/DTCs, a novel in  situ strategy 
of immunostaining-FISH (iFISH®) combining karyotypic 
CEP-FISH and phenotypic immunostaining of CD45 as 
well as tumor markers has been successfully developed 
to identify non-hematopoietic heteroploid tumor cells 
[7]. Immunostained proteins in/on CTCs or DTCs are 
unrestricted to either intracellular or extracellular anti-
genic epitopes of nuclear, cytosolic or membrane associ-
ated tumor biomarkers or epithelial markers [56]. iFISH® 
technology provides numerous choices for people to 
target any of the desired tumor biomarkers to be inves-
tigated or any of the chromosome to be enumerated or 
examined.
Principle and diverse types of tumor biomarker-iFISH 
are described in Fig. 3a. CD45 IF staining was applied to 
distinguish hematopoietic vs non-hematopoietic cells. 
Among three of CD45 negative non-hematopoietic cells, 
additional IF staining showed heterogeneously expressed 
tumor biomarker (for instance CK18 in this study) in Cell 
1 and 2. Whereas FISH examination indicated Cell 1 and 
3 had heteroploid chromosome (chromosome 8 in this 
study). Overlayed iFISH image indicated that instead of 
two CTCs respectively identified by immunostaining or 
FISH alone, all of 3 non-hematopoietic cells were CTCs. 
Trisomy Cell 1 had strong CK18 expression, diploid Cell 
2 showed weak expression of CK18, whereas trisomy 
Cell 3 had no detectable CK18. Obtained results indi-
cate that neither immunostaining nor FISH alone is able 
to identify all the CTCs which display great phenotypic 
and karyotypic heterogeneity. Additional different types 
of tumor biomarker-iFISH, including CA19-9, CK18, 
EpCAM and HER2-iFISH are revealed in Fig. 3b.
Comparing to current conventional identification 
approaches, in  situ phenotyping and karyotyping of 
tumor cells performed by iFISH is of particular and 
unique superiority with respect to detecting various 
CTCs and DTCs. In addition, iFISH enables classifying 
CTCs/DTCs into diverse subtypes by in  situ phenotyp-
ing of the tumor biomarkers and karyotyping of chro-
mosome ploidy (in situ PK CTC or DTC) [7]. A high 
frequency of CTC subtypes with diverse CK18 expres-
sion and aneuploidy of chromosome 8 has been identified 
and characterized by us in several types of solid tumor 
including renal cell, HCC, ovarian, colorectal, pancreatic, 
lung, esophageal and gastric carcinomas [7, 31]. Illus-
tration of the CTCs/DTCs subtypes possessing distinct 
clinic significance [31] will help guide more specific and 
significant genotypic, proteomic and functional analyses 
performed on the targeted single tumor cell [57, 58].
Moreover, in contrast to conventional lengthy FISH 
protocol which takes more than 20 h, the time required 
for entire iFISH experiment including antibody staining 
is as short as 3–4 h, which is very valuable for rapid clini-
cal diagnosis.
Application of subtraction enrichment (SE)‑iFISH
Efforts from others to improve CTC detection have 
mainly focused on either isolation or identification, 
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respectively. However, an effective CTC detection truly 
relies on both well-established isolation and identification 
strategies. In view of failure to detect EpCAM negative 
“uncapturable” and CK negative “invisible” CTCs due to 
inevitable drawbacks of current EpCAM/CK-dependent 
methodologies, an integrated tumor cell surface mole-
cule-independent SE-iFISH® platform has been systemat-
ically developed and clinically validated (Fig. 4) [7, 9, 31].
Regardless of cellular heterogeneity, inherited down-
regulation and/or absence of CKs and EpCAM [4, 59], 
as well as CTC size variation ranging from similar or 
smaller than WBCs up to large tumor cells [6, 10, 12], 
SE-iFISH® enables expeditious detection of CTCs, DTCs 
and CTMs in regard to efficient enrichment, identifica-
tion and classification of hypotonic-free, heterogeneous 
subpopulations of non-hematopoietic heteroploid can-
cer cells. Our previous and on-going studies showed that 
those CTCs could be shed from various types of epithe-
lial solid tumor, including lung, glioma, melanoma, oste-
osarcoma, pheochromocytoma, parathyroid, esophageal, 
breast, pancreatic, gastric, colon, cervical, ovarian, blad-
der, renal cell and HCCs in murine or patient’s periph-
eral blood, or disseminated in bone marrow, CSF, urine, 
malignant pleural effusion or ascites, despite existence 
of numerous CK positive mesothelial cells. Obtained 
viable and native tumor cells free of antibody perturb-
ing are eligible for subsequent primary tumor cell cul-
ture (unpublished results) or genetic analyses performed 
on individual CTC. Successful EGFR mutation analysis 
performed on the single laser capture micro-dissected 
(LCM) lung cancer CTC enriched from patients has been 
recently published [58].
Comparing to conventional EpCAM/CKs-dependent 
strategy, SE-iFISH® demonstrated higher sensitivity 
for CTC detection, showing 90.5  % positive rate of SE-
iFISH® vs 54.8 % of CellSearch on the identical popula-
tion of gastric cancer patients [31]. Similar high CTC 
positivity detected by SE-iFISH® was also observed on 
lung (92 %) and esophageal (87 %) carcinoma patients [7].
Investigation of how each CTC subpopulation corre-
lates with distinct clinical outcomes is of particular sig-
nificance. In situ phenotyping and karyotyping analysis 
of CTC subtypes (in situ PK CTC) performed by iFISH® 
indicated that among CK18 negative CTCs enriched 
from gastric cancer patients, trisomy chromosome 8 
CTCs may possess intrinsic resistance to the chemo-
therapeutic agent cisplatin, whereas tetra- and pentas-
omy subtype developed acquired resistance [31]. Similar 
results identifying both cisplatin-sensitive and insensitive 
CTCs in gastric neuroendocrine cancer PDX mice was 
also recently reported [9]. Of which, CTCs were detected 
in 200  μl of blood periodically collected for nine times 
from cisplatin treated or vehicle PDX mice. Cisplatin-
sensitive or insensitive CTC subtype could be identified 
and classified by CK18–iFISH®.
Clinical relevance of CTC and DTC subtypes character-
ized by a number of established tumor biomarkers-iFISH® 
(such as HER2 [31], CK18, PanCKs, EpCAM, α-fetoprotein 
[AFP], CD133, CA19.9, Vimentin, etc.) to prognosis, 
metastasis, drug resistance and recurrence in large cohorts 
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Fig. 3 Principle of iFISH. a Combined in situ phenotypic immu-
nostaining and karyotypic FISH demonstrate that among 3 CD45 
negative non-hematopoietic cells, immunostaining of tumor 
biomarker (CK18 in this study) alone indicates that Cell 1 and 2 
respectively have high and low CK18 expression, and Cell 3 has no 
visible CK18 detected; whereas image of FISH alone performed 
with CEP of chromosome (chromosome 8 in this study) shows that 
Cell 1 and 3 are abnormally triploid, and Cell 2 are diploid. Merged 
iFISH image demonstrates that all of Cell 1–3 are CTCs. Cell 1 has 
triploid chromosome 8 with strong CK18 expression; Cell 2 pos-
sesses disomy of chromosome 8 with low CK18 expression; and Cell 
3 shows triploid chromosome 8 with negative CK18 expression. b 
Diverse tumor biomarker-iFISH, including CA19-9, CK18, EpCAM, 
and HER2-iFISH are illustrated. Experimental protocol of SE-iFISH was 
previously published [7]. Briefly, 6–8.5 ml peripheral blood, collected 
into a tube containing acid citrate dextrose anti-coagulant (Becton–
Dickinson, Franklin Lakes, NJ, USA), were subjected to centrifuging 
to remove plasma, followed by centrifuging again on the top of 
non-hematopoietic cell separation matrix to remove RBCs. Remain-
ing WBCs were incubated with anti-WBC immunomagnetic beads, 
and subsequently loaded on the separation matrix, then spun down. 
Cell pellet thoroughly mixed with the cell fixative was applied on the 
formatted and coated CTC slide. The air dried samples were subjected 
to FISH probe hybridization and antibody staining performed with 
Alexa Fluor 594 conjugated monoclonal anti-CD45 and Alexa Fluor 
488 conjugated with the indicated antibody [56], followed by image 
collection and analysis
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our active investigation. Subsequent NGS genetic analy-
ses and comparison of the targeted single CTC or DTC vs 
neoplastic cells in primary and metastatic lesions will pro-
vide very valuable insights for people to understand and 
illustrate mechanisms of tumor metastasis.
It is anticipated that SE-iFISH® could help promote 
more specific and significant analyses on pooled or sin-
gle CTC/DTC, and may also help establish polyclonal 
or even monoclonal patient CTC/DTC subtype-derived 
“xenograft”(CDX or DDX) mouse models [60].
Conclusion
In view of highly heterogeneous and dynamic expres-
sion or absence of EpCAM and CK in CTCs and DTCs, 
the epithelial marker-independent SE-iFISH® platform 
provides additional choice and flexibility, with higher 
sensitivity and specificity, to detect various CTCs/DTCs 
without being restricted and biased to the only both 
EpCAM and CK positive neoplastic cells. In situ pheno-
typing of tumor biomarker expression and karyotyping of 
chromosome ploidy performed by iFISH® will shed light 
on additional intriguing clinical utilities and significance 
of diverse subtypes of CTC/DTC, and will also help guide 
more meaningful studies performed on the targeted sin-
gle tumor cell enriched from different types of cancer 
patient or tumor animal models.
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